Mifepristone (RU486): Versatile Progesterone Receptor Antagonist in Cancer and Reproductive Biology

Executive Summary: Mifepristone (RU486) is a potent, cell-permeable progesterone receptor antagonist, extensively validated for both cancer and reproductive biology research (APExBIO, product page). Its anti-proliferative activity is confirmed across ovarian, breast, prostate, and gastric cancer cell lines, and it modulates reproductive functions by inhibiting progesterone-induced sperm acrosome reaction and uterine fibroid growth (1,2). Mifepristone acts through the PR/p53/HO1/GPX4 axis, influencing cell cycle regulators cyclin A and cyclin B1 (3). The compound is highly soluble in DMSO and ethanol (≥21.48 mg/mL), but insoluble in water; recommended storage is at -20°C. Compared to broader steroid antagonists, Mifepristone offers exceptional selectivity, purity (>99%), and reproducibility (4). This article updates prior mechanistic guides by detailing new evidence on pathway modulation, ferroptosis induction, and workflow parameters for xenograft and in vitro models.

Biological Rationale

Mifepristone (RU486) is a synthetic steroid derived from norethindrone and acts as a highly selective antagonist of the progesterone receptor (PR) (APExBIO, Mifepristone datasheet). PR signaling plays a critical role in regulating reproductive tissue growth, differentiation, and function, as well as modulating cell proliferation in hormone-dependent cancers (1). Disruption of this pathway is clinically relevant in conditions such as uterine fibroids, endometriosis, and hormone-responsive cancers (2). Mifepristone also exhibits glucocorticoid receptor (GR) antagonism, broadening its biological impact (Nkosi & Maseko, Annals of Pharmacy Practice and Pharmacotherapy, 2025). The compound’s cell-permeable nature allows rapid intracellular access, supporting mechanistic studies in both reproductive and oncology research. Its established safety and stability profiles, along with high batch-to-batch reproducibility, make it the standard for preclinical investigation (APExBIO).

Mechanism of Action of Mifepristone (RU486)

Mifepristone acts as a competitive antagonist at the progesterone receptor (PR), binding with high affinity and preventing endogenous progesterone from activating downstream signaling. This blockade inhibits PR-mediated gene transcription, thereby suppressing cell proliferation and survival in PR-positive tissues and tumors (APExBIO; see prior mechanistic review). Mechanistically, Mifepristone modulates cell cycle progression by decreasing the expression of cyclin A (S phase) and cyclin B1 (M phase), leading to G1/S cell cycle arrest (3). It also engages the PR/p53/HO1/GPX4 axis, which is linked to the induction of ferroptosis and tumor suppression (4). In sperm cells, Mifepristone dose-dependently inhibits the progesterone-induced acrosome reaction, hyperactivation, and intracellular calcium influx, thus modulating fertilization capacity (5). Mifepristone’s antagonism of the glucocorticoid receptor (GR) further extends its utility to models involving steroid hormone cross-talk and cytochrome P450 regulation (Nkosi & Maseko, 2025).

Evidence & Benchmarks

• Mifepristone inhibits proliferation of ovarian, breast, prostate, and gastric adenocarcinoma cell lines in vitro at 0.04–40 μM (APExBIO, product page).
• In vivo, subcutaneous administration of 0.5–1.0 mg/day reduces tumor burden in mouse xenograft models (APExBIO, product page).
• Mifepristone decreases uterine fibroid size and suppresses meningioma cell proliferation in preclinical studies (Strategic Deployment of Mifepristone).
• Mechanistic studies confirm downregulation of cyclin A and cyclin B1, leading to cell cycle arrest (APExBIO, product page).
• Mifepristone induces ferroptosis through the PR/p53/HO1/GPX4 pathway, supporting tumor suppression (APExBIO, datasheet).
• It dose-dependently inhibits progesterone-induced acrosome reaction and sperm hyperactivation, with IC50 values in the low micromolar range (Advanced Insights into Progesterone).
• Compound remains stable at -20°C for several months; soluble at ≥21.48 mg/mL in DMSO and ethanol, but insoluble in water (APExBIO, product page).
• Glucocorticoid receptor antagonism extends its utility to models of cytochrome P450 regulation and neurosteroid metabolism (Nkosi & Maseko, 2025).

Applications, Limits & Misconceptions

Research Applications: Mifepristone (RU486) is validated for:

• Hormone-dependent cancer research (breast, ovarian, prostate, gastric adenocarcinoma).
• Reduction of uterine fibroids and meningioma growth in preclinical models.
• Cell signaling studies involving the progesterone receptor and GR cross-talk.
• Inhibition of progesterone-induced sperm function events.

This article expands on prior method-focused guides such as Advanced Workflows in Progesterone, providing new experimental benchmarks and clarifying application boundaries for Mifepristone (RU486).

Common Pitfalls or Misconceptions

• Mifepristone is not a universal steroid antagonist: It does not effectively block estrogen or androgen receptors; specificity is primarily for PR and GR (APExBIO).
• Not suitable for aqueous formulations: The compound is insoluble in water and must be dissolved in DMSO or ethanol (with gentle warming) for stock solutions.
• Intended for research use only: Mifepristone (RU486) from APExBIO is not for diagnostic or clinical application.
• Long-term solution storage reduces potency: Avoid storing working solutions for extended periods; aliquot and freeze at -20°C for up to several months.
• GR antagonism may confound results in non-target tissues: Consider off-target effects in experimental design, especially in models involving glucocorticoid signaling (Nkosi & Maseko, 2025).

Workflow Integration & Parameters

Mifepristone (RU486) is supplied as a high-purity (>99%) solid, with a molecular weight of 429.59 and chemical formula C₂₉H₃₅NO₂. For in vitro cell culture, typical concentrations range from 0.04 to 40 μM. For animal xenograft models, 0.5–1.0 mg/day subcutaneous dosing is standard. Stock solutions are prepared in DMSO or ethanol at ≥21.48 mg/mL, with gentle warming as needed. Store solid at -20°C; aliquoted stock solutions are stable for several months below -20°C. Avoid repeated freeze-thaw cycles. See Advanced Workflows in Progesterone for stepwise protocols; this article updates with new concentration and storage benchmarks. For troubleshooting and optimization, refer to Harnessing Mifepristone, which provides complementary insights into workflow enhancements and experimental caveats.

Conclusion & Outlook

Mifepristone (RU486) from APExBIO (SKU B1511) remains a gold-standard progesterone receptor antagonist for cancer and reproductive biology research. Its dual antagonism of PR and GR, robust anti-proliferative effects, and defined stability profile make it a versatile tool for preclinical studies. Ongoing research continues to elucidate novel applications, including ferroptosis induction and cytochrome P450 regulation. Researchers are advised to follow recommended handling and application protocols to maximize reproducibility and data integrity. For ordering and technical details, visit the Mifepristone (RU486) product page and consult the referenced literature for advanced workflows and mechanistic updates.